



Breast Cancer and Ductal Carcinoma In-Situ Site Study 2015

Dr. Lata Thatai, MD



Site Study Overview

- National Comprehensive Cancer Network Clinical Practice Guidelines
 - Triple negative breast cancer BRCA testing eligible 2010
 - Ductal Carcinoma In-Situ (DCIS) BRCA testing eligible in 2011
- The data for this study was extracted from the Oncology Data Base in the Cancer Registry for Breast Cancer Cases from 2013-2014.

Study Population and Demographics

- Patients who were diagnosed with breast cancer or DCIS in 2013 or 2014 were included in the study
- Study N = 78 patients
 - Average age: 57
 - 99% of patients were female

| Age Distribution | |
|--------------------|---------|
| Age Range in Years | 38 - 84 |
| Mean in Years | 57 |
| Mode in Years | 55 |
| Median in Years | 61 |

| Study Demographics | |
|-----------------------|-----------|
| Male Patients | 1 |
| Female Patients | 77 |
| Total Patients | 78 |

Pathology of Study Population

| Pathology | |
|--|----|
| Invasive Cancer | 58 |
| Ductal Carcinoma In-Situ | 24 |
| Invasive Ductal | 47 |
| Invasive Lobular | 13 |
| Other: Ductal, Invasive Adenocarcinoma | 4 |

- Majority of patients had invasive cancer (58 patients)
- Out of patients with invasive ductal, 3 patients had both lobular and ductal
- For patients with other pathologies, there were 3 patients with other ductal, and 1 patient with other invasive adenocarcinoma

BRCA Eligibility Criteria

Any person with or a family history of:

1. Age 50 or under with a Breast Cancer diagnosis
2. Ovarian Cancer any age
3. Two primary Breast Cancers
4. Male Breast Cancer
5. Triple Negative Breast Cancer
6. Pancreatic cancer with a breast or ovarian cancer
7. Ashkenazi Jewish Ancestry with an HBOC associated cancer
8. Two or more relatives with breast cancer, 1 under age 50
9. Three or more relatives with breast cancer at any age
10. A previously identified BRCA mutation in the family

Hormone Receptor Status

- Out of 78 patients:
 - 7.7% (6 patients) had triple negative disease
 - 83% (65 patients) had hormone positive disease

BRCA ELIGIBLE

- 35% (27 Patients) were eligible for testing
- 65% (52 Patients) were non-eligible for testing

Testing Offered

- 25 Patients were offered testing
- 76% (19 patients) accepted testing

BRCA Staging

- 19 patients accepted the BRCA Testing
- Out of the 19 patients 5.2% (1 patient) was positive. 94.8% (18 patients) were negative.

| Stage | Count |
|--------------|-----------|
| IIB | 7 |
| IA | 7 |
| IIIB | 1 |
| IIA | 1 |
| IIIA | 1 |
| 0 | 1 |
| UNK | 1 |
| Total | 19 |

Reasons Testing Not Done

- Unknown: 1
- Ovarian Cyst, no Cancer: 1
- Patient Declined: 2
- Insurance Denial: 2

Reasons for Not Testing:

- 1 Patient was eligible for testing but did not follow up
- 1 Patient eligible for testing: unknown: Family history of breast and ovarian cancer. Patient had 2 primaries in same breast, 6 years apart

Clinical Pearls

1. The NCCN guidelines changed in 2010 to include triple negative breast cancer and in 2011 to include DCIS. We should ensure that all patients with these diagnoses are offered BRCA testing if they meet criteria.